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1. Introduction 
In the pharmaceutical and partly also in the fine chemicals industry many chemical 
conversions require stoichiometric amounts of reagents, and thus generate large amounts of 
waste [1, 2]. This is in contrast to the production of bulk chemicals which mostly relies on 
catalysis. This difference can be explained by the higher complexity of pharmaceuticals and 
fine chemicals which makes catalysis more demanding and process development more 
expensive. 
According to Sheldon’s classification [3], most vitamins are typical fine chemicals with 
production volumes of about 100 to 10'000 tons per year. Some vitamins can be placed in the 
class of bulk chemicals. Typically these compounds have been produced industrially for 
decades in multi-step syntheses with high overall yields. The application of catalytic 
methods in the highly competitive field of vitamins has increased significantly in recent 
years because of price pressure on these products. Research and development is thus driven 
by the necessity to reduce waste, use less toxic reagents and solvents, improve energy 
efficiency, recycle catalysts and reagents, and combine unit operations to reduce costs and 
achieve more sustainable processes. These goals are mostly in accordance with the twelve 
principles of “green chemistry”[4,5,6]. 
Catalytic hydrogenation is certainly the most widely applicable method for the reduction 
of organic compounds and belongs to the most important transformations in chemical 
industry. Catalytic hydrogenations in the fine chemicals industry are usually carried out 
with heterogeneous catalysts. Homogeneous catalysts are typically applied for highly 
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selective transformations, particularly enantioselective reductions. In the case of full 
recycling of heterogeneous or homogeneous catalysts, hydrogenation with molecular 
hydrogen is an atom economic transformation and undoubtedly the cleanest possible 
method for reducing a compound. Alternatively, hydrogen donors such as isopropanol or 
formic acid can be applied in transfer hydrogenations. In the field of catalytic 
hydrogenation reactions several significant inventions have been reported in the last  
150 years. Sabatier and co-worker investigated the application of highly dispersed metals, 
e.g. nickel, in the hydrogenation of organic compounds [7,8]. The elective semi-
hydrogenation of C≡C-bonds in presence of lead-doped palladium on calcium carbonate 
catalysts found by Lindlar was a further milestone in the field of catalytic hydrogenation 
reactions [9-11]. During the last decades asymmetric hydrogenations, pioneered by W.S. 
Knowles and R. Noyori, were a further highlight in the field of hydrogenation applied in 
organic synthesis [12,13]. 
Catalytic hydrogenations can be carried out in a variety of ways, either in the liquid or gas 
phase and in batch-wise or continuous mode. In continuous processes usually fixed-bed 
reactors or fluidized-bed reactors are used. The suitable choice of a reactor system depends 
on various factors such as, in particular, the choice of catalyst, the reaction conditions, heat 
formation, space-time-yield, residence time, hydrogen pressure, mass-transport phenomena, 
temperature, solvent and economic reasons. 
In this contribution we will focus on industrially important catalytic hydrogenation 
reactions which are of interest for DSM Nutritional Products concerning the manufacture of 
vitamins, carotenoids and nutraceuticals. The various hydrogenations are organized by 
reaction types, rather than by the products prepared: hydrogenations of C=C double bonds, 
selective semi-hydrogenations of C≡C triple bonds, hydrogenations of C=X/C≡X multiple 
bonds (X = oxygen or nitrogen), and stereoselective hydrogenations.  
2. Hydrogenation of C=C double bonds  
Probably the most common hydrogenation reaction performed in industry is the 
hydrogenation of carbon-carbon double bonds. A wide variety of catalysts are available 
from commercial suppliers and this transformation is considered a robust and atom-
economical reaction. Even so, careful optimisation of the reaction conditions can be required 
to obtain full conversion and reduce or eliminate by-products. This is also important in the 
synthesis of vitamins and fine chemicals. 
(all-rac)-α-Tocopherol (3) is the economically most important member of the group of 
vitamin E compounds, due to its biological and antioxidant properties. This fat-soluble 
vitamin is produced on a scale of >30’000 tonnes per year (mostly in form of its acetate 
derivative 4) for applications in human and animal nutrition. One of the key building blocks 
for the chemical production of synthetic vitamin E is trimethylhydroquinone (TMHQ, 1), 
which is converted into (all-rac)-α-tocopherol (3) by condensation with (all-rac)-isophytol (2, 
Scheme 1) [14-16].  
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Scheme 1. Final steps of the chemical production of vitamin E. 
The synthesis of isophytol can be carried out starting from acetone (5) and building up the 
isoprenoic side chain by a sequence of C2 and C3 elongations (via 8 and 10, Scheme 2). 
Another approach starts from citral (9) followed by reaction to linalool (11) and 
elongation to geranylacetone (13) [14,15]. Routes to 9 based on prenyl chloride  
and myrcene (6) are described in literature but are not competitive. The use of cheap 
isobutene (7) is preferred which represents also an access to other isoprenoic building 
blocks, e.g. 14. The C3-elongation can be carried out by Saucy-Marbet or Carroll reactions 
and the C2 elongation by ethynylation or vinylation reactions (vinyl Grignard addition) 
[1]. In such reaction sequences several hydrogenations of C=C bonds are necessary. A key 
intermediate in the synthesis of isophytol (2) is hexahydropseudoionone (12), which can 
be produced from pseudoionone (10) or geranylacetone (13). In the past  
the hydrogenation reactions were carried out batch-wise in presence of a Pd/C catalyst 
below 80 °C and <10 bar pressure [17]. This hydrogenation was also investigated using 
Pd- or Rh-containing polymers on Al2O3 [18]. The liquid phase hydrogenation of 
pseudoionone (10), geranylacetone (13) or dihydrogeranylacetone in presence of a 
suspended catalyst in a special reactor which allows an easy hold-up of the catalyst has 
been described in [19]. The synthesis of these saturated ketones in a continuous fixed-bed 
mode applying a Pd catalyst supported on SiO2 results in excellent yield under nearly full 
conversion [20].  
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Scheme 2. Synthesis of isophytol (E/Z isomerism of olefins is omitted here). 
The other key intermediate for the synthesis of vitamin E, TMHQ (1), is accessible via 
catalytic hydrogenation of trimethylbenzoquinone (TMQ, 15) using a palladium on carbon 
catalyst (Scheme 3).  
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Scheme 3. Catalytic hydrogenation of TMQ to TMHQ. 
 
Hydrogenation in the Vitamins and Fine Chemicals Industry – An Overview 73 
The hydrogenation is usually carried out in a continuous mode at medium to low pressure 
and elevated temperature to prevent crystallization of the product from the reaction 
mixture. Yields are generally quantitative. 
Alternatively, a range of different Pd-catalyzed hydrogenation conditions can be found in the 
literature, e.g. using Pd/C in solvents like carboxylic esters [21] or acetone [22], or palladium on 
acidic [23,24] or basic oxides [25] in lower alcohols. Also a Pt-catalyzed hydrogenation has 
been described using platinum nitrate and aluminium oxide in i-butanol [25]. 
An alternative access to TMHQ (1) starts from less methylated 1,4-benzoquinones, e.g. 2,6-
dimethylbenzoquinone (2,6-DMQ, 16), which is first hydrogenated to 2,6-
dimethylhydroquinone (17) and methylated later, e.g. by aminomethylation via 18 followed 
by hydrogenolysis to TMHQ (1) (Scheme 4) [26].  
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Scheme 4. Synthesis of TMHQ from 2,6-DMQ. 
The K-vitamins are a group of substituted 2-methyl-1,4-naphthoquinones with (or without) 
a prenyl chain of different length in C-3 position (Figure 1). The core unit of all K-vitamins is 
menadione (vitamin K3, 21) [27,28]. The standard synthesis of vitamins K1 and K2 (19,20) is 
the coupling of the aromatic unit with the (poly)prenyl side chain, similar to vitamin E. The 
direct coupling of the side chain to menadione (21) is not possible; therefore a key step is the 
hydrogenation of menadione to menadiol (22) so that alkylation can take place. The 
hydrogenation is usually carried out batch-wise using a palladium on carbon catalyst. 
After esterification, condensation with isophytol (2) according to the methods of the group 
of Isler [29,30] or Hirschmann et al. [31], and subsequent saponification the hydroquinone is 
then re-oxidized to the corresponding naphthoquinone, e.g. in the industrial preparation of 
synthetic vitamin K1 (phylloquinone, Konakion®, 23) (Scheme 5).  
A remarkable stereoselective hydrogenation of a trisubstituted olefinic C=C double bond 
was used in several total synthesis routes to the water-soluble vitamin (+)-biotin (26, Scheme 
6) [32]. This product is produced on a scale of about 100 tonnes per year, and only the 
(3aS,4S,6aR)-stereoisomer exhibits full biological activity. Stereocenter C-4 of the thiophane 
ring can be introduced by catalytic hydrogenation of the exocyclic olefin 24 with undefined 
double-bond stereochemistry on Pd/C or other heterogeneous catalysts, yielding 25 with the 
desired all-cis relative configuration at centers C-4, C-3a, and C-6a. The N-benzyl protecting 
groups are stable under those conditions. This strategy, originally developed by Goldberg 
and Sternbach [33,34], was later on used by other groups in various syntheses of racemic 
and optically active intermediates [32]. 
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Figure 1. Molecular structures of the different K vitamins. 
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Scheme 5. Chemical production of vitamin K1. 
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Scheme 6. Stereoselective heterogeneous hydrogenation in routes towards (+)-biotin. 
3. Semi-hydrogenation of C≡C triple bonds (Lindlar type)  
The semi-hydrogenation of carbon-carbon triple bonds to alkenes is one of the most useful 
hydrogenations for the production of vitamins, however careful choice of catalyst and 
reaction conditions are required to obtain high selectivity. In general, hydrogenation of 
acetylenes with a metal catalyst results in the formation of the fully saturated alkane 
product, since the second hydrogenation (alkene to alkane) is generally faster than the first 
(alkyne to alkene). However, as long as some of the starting alkyne remains in the reaction 
mixture, selectivity can be high since the alkynes bind more strongly to the metal surface. 
The selectivity can be enhanced by the use of suitable catalyst poisons which modify the 
activity of the metal catalyst. 
One of the most widely used and most selective catalysts is the one originally developed by 
Lindlar [9,11]. With this catalyst, the palladium supported on calcium carbonate is doped 
with a lead acetate solution during manufacture. This catalyst can then be used either 
directly in the hydrogenation or modified further by an organic compound such as an 
amine. Since the hydrogen is delivered from the metal surface to the alkyne, usually high 
selectivity is obtained for the Z-(cis)-alkene product. “Lindlar catalysts” generally have 5% 
palladium loading and 2-5% lead loading, depending on the application. 
One of the earliest uses of the catalyst developed by Lindlar was the semi-hydrogenation of 
a vitamin A key intermediate (27, Scheme 7) to give tetraene 28. Whilst this could be 
achieved with poisoned palladium on charcoal or palladium on calcium carbonate [35], 
selectivities were significantly higher with the lead-doped catalyst and the reaction could 
easily be stopped after the uptake of just one equivalent of hydrogen gas. 
OH
OH
OH
OH27 28
OAc
vitamin A acetate  
Scheme 7. Semi-hydrogenation of a vitamin A intermediate. 
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Since this early success the “Lindlar catalyst” (as it has become known) has been used in 
many different production processes. It is of particular importance in the synthesis of 
vitamins A & E and also intermediates for the fragrance industry. An important starting 
material in DSM Nutritional Products’s production of such compounds is methylbutenol 
(MBE, 30, Scheme 8). MBE is synthesised by the partial hydrogenation of the corresponding 
alkyne MBY (29) in a batch-wise process. Selectivity is very high (>98%) and the catalyst can 
be recycled multiple times.  
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Scheme 8. Semi-hydrogenation of MBY. 
From MBE, the chain is extended in a sequential manner to obtain dehydroisophytol (31, 
Scheme 9). This is then reduced in another semi-hydrogenation to give isophytol (2, cf. 
Scheme 2) [15]. Isophytol can then be coupled with TMHQ (1), as described previously, to 
form α-tocopherol (cf. Scheme 1). As with MBY-MBE, the hydrogenation is carried out in a 
batch-wise process at 2-5 bar hydrogen pressure. 
 
HO OH
31 isophytol 2  
Scheme 9. Preparation of isophytol by semi-hydrogenation. 
Two compounds of interest to the fragrance industry are linalool (11) and linalyl acetate (33, 
Scheme 10). Both have pleasant floral and spicy odours and are found in a wide range of 
natural flowers and spice plants. Their main uses are as perfume components in soaps, 
shampoos and lotions. They can both be synthesised by semi-hydrogenation of 8 and 32 
using Lindlar catalysts, however the reaction conditions had to be optimised independently 
since even minor changes to the substrate structure can significantly affect the 
hydrogenation selectivity. 
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Scheme 10. Production of linalool and linalyl acetate by semi-hydrogenation. 
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As an extension to the work above, another fragrance compound, dimethyloctenol (DMOE, 
36), can be prepared by the combination of a hydrogenation of a C=C double bond and a 
selective semi-hydrogenation of a C≡C triple bond (Scheme 11). Methylheptenone (34) can 
be hydrogenated with a range of Pd/C or Pd/Al2O3 catalysts to give methylheptanone (35). 
The reaction was run without solvent at a range of temperatures (30-80 °C) and pressures (1-
10 bar hydrogen). The latter compound was ethynylated to give the alkyne 14, which can 
undergo semi-hydrogenation with high selectivity (up to 95%) to give the desired tertiary 
allyl alcohol 36. Lindlar catalysts with varying amounts of lead-doping were successful at 
moderate temperatures (20-40 °C) and pressures (1-10 bar hydrogen) [36].  
New approaches for the application of Lindlar-type catalysts are the use of supported 
palladium nanoparticles. By carefully controlling their preparation, a narrow range of 
diameters can be obtained and deposited on a carbon support [37,38]. These catalysts allow 
the hydrogenation of C≡C bonds with low metal loadings and in several cases with a high 
selectivity, e.g. hex-3-yne can be hydrogenated to hex-3-ene in high selectivity at full 
conversion, however to the best of our knowledge, these have not yet been applied on an 
industrial scale for the production of vitamins and fine chemicals. 
 
HO OH
O O
DMOE 36
34 35
14  
Scheme 11. Synthesis of DMOE by combination of two different kinds of hydrogenation. 
Further trends in the research on Lindlar hydrogenations are focusing on the addition of 
FeCl2 and tetramethylammonium chloride to the catalyst, and the use of palladium on metal 
sintered fibers. This allows the hydrogenation of triple bonds in a continuous reaction mode, 
also with low Pd loadings, in which Pb doping is not necessary [39-42].  
Resveratrol (40, Scheme 12) is a polyphenol that can be isolated from natural sources such as 
red grapes or giant knotweed. It has attracted significant attention due to its possible health 
benefits in areas such as anti-cancer, anti-aging, anti-inflammatory and cardiovascular 
protection. The synthesis of resveratrol has been reported a number of times and can be 
industrially performed using Mizoroki-Heck coupling of 3,5-diacetoxy-styrene and 4-
acetoxybromobenzene as key step [43,44].  
An alternative approach to resveratrol uses the selective hydrogenation of tolan derivatives 
37 in presence of a Lindlar-type catalyst to form intermediate 38 [45]. The precursor 37 can 
be synthesized by Sonogashira coupling (Scheme 12). In general this procedure can be 
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applied to the synthesis of electron-rich stilbene derivatives as in the preparation of natural 
compounds like combretastatin (39) [46]. 
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Scheme 12. Synthesis of combretastatin and resveratrol via Sonagashira coupling and semi-hydrogenation. 
Z-Butene-1,4-diol (42) is an intermediate in the synthesis of vitamin B6 (43), and is 
synthesized by selective hydrogenation of butynediol (41) in presence of a Pd/CaCO3 
catalyst (Scheme 13) [47,48]. The hydrogenation also proceeds well in water. The application 
of Pd/C or Pd/Al2O3 has been described under similar conditions [49]. The hydrogenation 
can also be carried out in a monolith bubble column reactor. Full conversion and high 
selectivity can be achieved in presence of a Pd-catalyst [50]. 
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Scheme 13. Semi-hydrogenation of butynediol for vitamin B6. 
As described above, Lindlar hydrogenations are usually carried out in a batch-wise mode in 
presence of a Pb-doped Pd catalyst on a calcium carbonate carrier. However, new trends in the 
selective semi-hydrogenation of C≡C bonds are continuous processing and the application of 
environmentally friendly solvents. The application of supercritical fluids (sc-fluids) in fine 
chemical processes, e.g. extractions or as process solvent is well documented [51].  
Lindlar-type hydrogenations in supercritical fluids, e.g. sc-CO2, can be carried out in a 
continuous manner applying a plug-flow reactor set-up. The set-up allows the usage of a 
new type of Pd-catalyst, amorphous Pd81Si19 in a Pb-free system [52].  
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4. Hydrogenation of C=O and C≡N functional groups 
As well as the hydrogenation of C-C multiple bonds, the hydrogenation of C-X multiple 
bonds is used extensively in the production of vitamins and fine chemicals. 
L-Ascorbic acid (vitamin C, 46) is the vitamin that is produced on the largest volume 
worldwide (approximately 100,000 tonnes per year). The most important method for its 
industrial manufacture is the Reichstein process [53], which transforms D-glucose (44) into 
L-ascorbic acid via a mixed series of high-yielding chemical and microbiological steps. In the 
first step of the synthesis sequence D-glucose is hydrogenated to D-sorbitol (45) in presence 
of a Ni-alloy catalyst (Scheme 14). The reaction is usually carried out at high pressure and 
elevated temperature in a batch-mode or continuous process. Under these conditions the 
product is obtained in high selectivity and almost quantitative yield with only minor 
amounts of D-mannitol and L-iditol as by-products.  
Alternatively to the catalytic hydrogenation, microbiological [54] and electrochemical [55] 
methods also are known for the reduction of D-glucose to D-sorbitol.  
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Scheme 14. Reduction of D-glucose to D-sorbitol in the Reichstein process for the synthesis of  
vitamin C. 
Vitamin B1 (thiamine chloride, 49, Scheme 15) contains two heterocyclic rings linked by a 
methylene unit. In all industrial syntheses, the key intermediate is Grewe diamine (48), onto 
which the thiazole ring is constructed. In general, the diamine is prepared by hydrogenation 
of a pyrimidino nitrile (47) using a nickel-alloy catalyst. This was first reported in 1944 by 
Huber [56] who found that the use of palladium and platinum supported catalysts gave 
significant amounts of secondary amine 50 as by-product. The use of nickel catalysts also 
gave significant quantities of secondary amines, but these could be reduced to less than 5% 
by the addition of ammonia to the reaction mixture. 
Modern industrial syntheses still use the same basic process, although optimisation has 
improved the reaction significantly, further reducing the unwanted by-products. Reactions 
proceed in a batch-wise process with a solvent saturated with ammonia at moderate (>10 
bar) hydrogen pressure to ensure high activity and throughput. The catalyst can be recycled 
multiple times and usually remains in the reaction after batch. The choice of nickel catalyst 
is also important and recently nickel-alloy catalysts (Centoprime®) have been developed that 
reduce amine by-products further [57-60]. 
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Scheme 15. Production of Grewe diamine for vitamin B1. 
Resveratrol (40) can be produced industrially by an alternative route to that described 
earlier (cf. Scheme 12). A key intermediate in this production is the benzylic alcohol 52 
[43]. This is prepared by the hydrogenation of acetophenone derivative 51 using a 
transition metal catalyst [61]. A number of catalysts can successfully perform this 
transformation, but the suppression of by-products is essential. Use of palladium or 
platinum on carbon resulted in yields of up to 90% (depending on the solvent); however 
levels of critical by-products were too high to be applied on large scale. The problems 
were solved by the use of nickel-alloy catalysts. Using these catalysts in ethyl acetate (2-10 
bar hydrogen) allowed the production of the required alcohol 52 in greater than 95% 
yield. In addition the catalyst can remain in the reactor and be recycled multiple times 
resulting in a cost effective process. 
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Scheme 16. Hydrogenation of a ketone for the synthesis of resveratrol. 
5. Stereoselective hydrogenation of C=C double bonds  
Stereoselective processes, in particular the asymmetric hydrogenation of C=C double bonds, 
play an increasingly important role in the total synthesis of isomerically pure biologically 
active products. The naturally occurring fat soluble antioxidant (2R,4’R,8’R)-α-tocopherol 
(53, Scheme 17) is not available in sufficient amounts from natural source starting material. 
In the course of the considerable efforts towards an economic total synthesis of 53 during 
the last decades [16], exceptionally efficient new asymmetric hydrogenation processes were 
developed for the introduction of chirality to the aliphatic tocopherol side chain.  
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Scheme 17. Asymmetric hydrogenation reactions of allylic alcohols in isoprenoid chemistry. 
The homogeneous asymmetric hydrogenation of allylic alcohols catalyzed by ruthenium 
complexes could be performed on pilot scale with substrate-to-catalyst ratios of up to 
150’000 (Scheme 17). The C10-building block (E)-54 was transformed into (R)-57 with >99% 
selectivity by using (S)-MeOBIPHEP (56, Ar = p-Tol, X = OCH3) as ligand. Under similar 
conditions, hydrogenation of (E)-55 gave (R,R)-58 (>98% RR) with the catalyst derived from 
(S)-p-Tol-BIPHEMP (56, Ar = p-Tol, X = CH3) [62]. 
Even two chiral centers can be introduced by the one-pot reduction of unfunctionalized 
trialkyl substituted olefins in the presence of Ir-BArF complexes containing chiral P,N-
ligands (Scheme 18). By applying this novel retrosynthetic concept, an (all-R)-tocopherol 
derivative could be obtained for the first time from the corresponding (all-E)-tocotrienol 
derivative in a collaboration of the Pfaltz group with DSM Nutritional Products. 
Asymmetric hydrogenation of γ-tocotrienyl acetate (R,E,E)-59 with pyridyl phosphinite 60 
yielded acetate 61 with complete conversion and excellent stereoselectivity (>98% R,R,R) 
[63,64].  
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Scheme 18. Asymmetric hydrogenation reactions of unfunctionalized trisubstituted olefinic double 
bonds. 
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A Rh(I)-catalysed highly diastereoselective hydrogenation is the basis for a very short 
synthesis of (+)-biotin (26) developed by Lonza and applied on a technical scale (Scheme 19). 
The hydrogenative key transformation was the result of a cooperation with the catalysis 
group of former Ciba-Geigy [65]. After ligand screening and optimisation, the conversion of 
substrate 63, easily accessible from diketene via cheap tetronic acid (62), could be improved 
to high selectivity (65a:65b >99:1) with ferrocene derived josiphos2 (64) as ligand. Although 
the synthesis via thiolactone 66 and subsequent stereoselective heterogeneous 
hydrogenation of olefin 67 (cf. Chapt. 2, Scheme 6, 23→24) was operated on tonne scale, 
production had to be terminated due to high production costs. The final debenzylation step 
to yield 26 led to destruction of the chirality in the expensive (R)-methylbenzylamine 
auxiliary used for introduction of one of the two nitrogen functionalities. 
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Scheme 19. Diastereoselective hydrogenation in the Lonza procedure to (+)-biotin. 
The chiral D-lactone 70 is the key intermediate in all other commercially interesting biotin 
syntheses (Scheme 20) [66,67]. In former times, diastereomeric acetals derived from 
hydroxylactone 69 were used. Meso-compound 72 (obtained from fumaric acid 68 via diacid 
71) was recognised as an easily available starting material for introduction of the optical 
activity. Classical optical resolution to form diastereomeric imides or ammonium salts, 
diastereoselective ring opening with chiral alcohols (e.g. → 74), as well as enzyme catalyzed 
transesterification reactions were used. All those processes, however, are elaborative and 
need chiral auxiliaries in stoichiometric amounts which have to be recycled. Often, 
additional protective group transformations are necessary. Until 2006, the direct 
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desymmetrisation of anhydride 72 to D-lactone 70 and further elaboration to thiolactone 73 
was only possible by reduction with expensive (R)-BINAL-H in over-stoichiometric 
amounts under low-temperature conditions [68], which is not applicable on larger scale.  
A breakthrough was achieved in an inter-company cooperation, between DSM Nutritional 
Products and the catalysis group of Solvias [66,67]. The asymmetric hydrogenation of 
anhydride 72 to D-lactone 70 with Ir- and Rh-complexes with atropisomeric ligands [69] 
yielded best results. After a short series of screening and optimisation experiments, full 
conversion and ee values of >95% could be reached, resulting in successful production trials 
on tonne scale (Scheme 21). The transformation of thioanhydride 75 to thiolactone 73 needed 
some more drastic reaction conditions, delivering lower selectivities and moderate yield 
(R)-Pantothenic acid (R-77) is naturally occurring as a component of coenzyme A and is 
essential for various biochemical processes. R-77 and its commercial form calcium (R)-
pantothenate are industrially produced by optical resolution from racemic pantolactone (RS-
76, Scheme 22) as the key intermediate. The latter is prepared from isobutyraldehyde, 
formaldehyde, and hydrogen cyanide, and subsequent acidic hydrolysis [70]. Alternative 
processes rely on the enantioselective hydrogenation of 2-oxopantolactone (78) [71]. With a 
rhodium catalyst containing mTolPOPPM as a ligand, high turn-over numbers (TON) of 
200'000 and high optical purity (91% ee) could be obtained. The heterogeneous version of 
this transformation using a Pt/alumina catalyst in the presence of a chiral modifier, e.g. 
cinchonidine, delivered very similar ee values [72]. 
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Scheme 20. Synthetic strategies for the introduction of optical activity into (+)-biotin. 
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Scheme 21. Preparation of an optically active lactone by catalytic asymmetric hydrogenation. 
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Scheme 22. Enantioselective hydrogenation of 2-oxopantolactone in the synthesis of pantothenic acid. 
(3R,3'R)-Zeaxanthin [(3R,3'R)-83] is found in the human eye and is of interest for the treatment 
of age-related macular degeneration (AMD) [73] which is a major cause of blindness in the 
Western World. (3R,3'R)-83 occurs in nature in corn (maize) and egg yolk. Its total synthesis 
starts from ketoisophorone (79, Scheme 23) which is efficiently transformed by yeast 
fermentation into the chiral intermediate (R)-levodione [(R)-80]. The overall reaction scheme 
consists of various reaction steps (via (R,R)-81, 82). Stereoselective hydrogenation of (R)-
levodione [(R)-80] to trans-actinol, however, was difficult to achieve [74].  
While the heterogeneous nickel catalyzed hydrogenation of (R)-80 yielded a 80:20 mixture of 
(R,R)-trans-actinol [(R,R)-81] and the corresponding (4S,6R)-isomer, the homogeneous  
Ru-BINAP catalyzed asymmetric hydrogenation gave only poor chemo- and 
enantioselectivities. The breakthrough could be achieved by a ruthenium catalyzed 
asymmetric transfer hydrogenation with isopropanol using a dianion complex [Ru(N-pTs-
ethylenediamine){-2H}(η6-arene)] [75]. At a substrate-to-catalyst ratio of around 1000,  
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high de values were obtained when performing the reaction at room temperature and 
reaction times below 24 h. This was the basis for up-scaling and transfer to technical 
implementation. 
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Scheme 23. Asymmetric transfer hydrogenation of (R)-levodione in the synthesis of (3R,3'R)-
zeaxanthin. 
6. Conclusions 
Various types of hydrogenation reactions are indispensable parts of economically and 
ecologically beneficial manufacturing processes towards valuable products in the vitamins 
and fine chemicals industry. The increasing importance of environmentally benign 
production methods is addressed by developing concepts for improving the efficiency of 
transformations, continuous processing and recycling, and achieving high chemo- and 
stereoselectivities, thus avoiding laborious separation protocols and waste formation. The 
examples presented and discussed in detail show many achievements in this field during 
recent decades, but also the necessity to further search for alternative solutions.  
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